You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
About Us
Back to Home
Corporate Profile
Hospital Overview
Vision and Mission
CGH Senior Management
CGH 88th Anniversary
Our Heritage
Milestones
Awards & Achievements
Annual Reports
Visitor Information
Visiting A Patient
Getting to CGH
Getting around CGH
Food & Amenities
Newsroom
News Articles
News Release
Publications
Health Library
Contact Us
Useful Contact Numbers
Email Contacts
Patient Feedback
Check News About CGH
Patient's Rights and Responsibilities
PDPA
Whistle-blowing Policy
Events
Patient Care
Back to Home
Conditions & Treatments
Conditions & Treatments
Find a Doctor
Find a Medicine
Specialties & Services
Clinical Specialties
Nursing
Allied Health Services
Specialist Centres / Services
Community Partners
Community Care Disciplines
Community Health Services
GP Resources
Your Clinic Visit
Visiting a Specialist
Visiting the Emergency Department
Patient Care Through Video Consultation
Outpatient Covid-19 Vaccination
Your Hospital Stay
Patient Journey
Support Groups
Advance Care Planning
E-Services
Make/Change Appointment
Billing & Payment
Your Hospital Stay
Medication Collection Modes
Request for Medical Report
Find a Doctor
Telemedicine
Forms
Patient Feedback
Tender
Health Buddy
Research & Innovation
Back to Home
Research in CGH
Core Facilities
Clinical Trials & Research Unit
Health Services Research
Office of Innovation
Shimadzu-CGH Clinomics Centre
Centre for Healthcare Assistive & Robotics Technology (CHART)
SingHealth Research
Education & Training
Back to Home
Undergraduate
Medical Undergraduate Education
Nursing
Allied Health
Postgraduate
Medical Postgraduate Education
Nursing
Allied Health
Professional Development
Continuing Medical Education
Changi Simulation Institute
Changi Surgical Skills Lab
Projects & Collaborations
TRaCS
About Us
ReXilience® Programme
Counselling Services
Resources
Events
Contact Us
SingHealth Academy
Careers
Back to Home
Why Choose Us
Working at CGH
Career Choices
Doctors
Nurses
Allied Health Professionals
Management & Administration
Ancillary & Support
Job Opportunities
Scholarship & Sponsorship
Healthcare Scholarship
CGH Sponsorship
Meet Our Students
FAQs
Career Events
Giving
Back to Home
Overview
Campaigns
CGH Health Fund
Changi Run 2024
Why Give
Empower Our Patients in Need
Advance Healthcare Excellence
Benefits of Giving
Get Involved
Ways to Give
Your Gift at Work
Be Informed
Honour Roll of Donors
Contact Us
Home
to skip to the main content on a page
to skip to the main content on a page
Home
>
events
>
research
>
IMCB SCSS Virtual Seminar Biomimicry of glycosaminoglycans in the bone marrow microenvironment
IMCB SCSS Virtual Seminar: Biomimicry of Glycosaminoglycans in the Bone Marrow Microenvironment
2020-06-22T10:39:06.0000000Z
SingHealth Events Page
604
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Facebook
Font Resize
A-
A
A+
Print
By
|
The article is contributed/written by
Download the original article
|||
Tags:
; ; ; ; ; ; ; ; ; ; ; ; ;
IMCB SCSS Virtual Seminar: Biomimicry of Glycosaminoglycans in the Bone Marrow Microenvironment
Facebook
Font Resize
A-
A
A+
Print
7/28/2020 11:00:00 AM
7/28/2020 12:00:00 PM
Venue:
Zoom
Audience:
Public
Cost:
Mesenchymal stem cell (MSC) therapy offers significant potential for musculoskeletal regeneration. However, the low abundance of MSCs in bone marrow aspirates necessitates expansion in culture before their clinical application. Such ex vivo expansion leads to a loss of stem cell characteristics and thus, unpredictable therapeutic outcomes. Studies of the MSC secretome have highlighted the importance of endogenous FGF2 for their survival and maintenance of stemness. This seminar will describe studies related to MSC potency and therapeutic efficacy, and how these attributes can be enhanced by sustaining endogenous FGF2 signalling through supplementation with an affinity-selected heparan sulfate (HS) co-factor. Microfluidic assays show that HS improves the bioavailability of FGF2, so providing more distant MSCs with a source of active FGF2. This results in the sustained growth of multipotent MSC over extended passaging. When used to treat osteochondral injuries in small and large animal models, MSCs preconditioned in an HS-rich microenvironment show improved ICRS II and O’Driscoll healing scores compared with control. Moreover, MRI shows reduced osteochondral lesioning following treatment with MSCs supplemented with HS, with Instron biomechanical testing highlighting an associated improvement in biomechanical properties. Collectively, these data indicate that modulation of endogenous FGF2 signals by select HS glycosaminoglycans represents an effective strategy for the bioprocessing of MSCs with sustained therapeutic potency.
https://www.stemcell.org.sg/registration-cool-28jul.html
Register here
Google Calendar
Outlook Calendar
iCal Calendar
Speaker Details
Prof Simon Cool
Director, Allogeneic Stem Cell Manufacturing (ASTEM)
Theme Leader, Advance Manufacturing for Biological Materials (AMBM)
Senior Principal Investigator & Professor (Adjunct Research)
Glycotherapeutics Group, Institute of Medical Biology (IMB)
Prof Cool received his BSc (Hons) and PhD degrees from the University of Queensland, Australia where he subsequently held a faculty position in the School of Biomedical Sciences until 2003. He then joined IMCB, A*STAR and in 2008 moved to IMB. Prof Cool is focused on developing novel glycosaminoglycan biomolecules that enhance tissue repair and control mesenchymal stem cell activity. He has 43 granted patents across 18 families in the field of glycosaminoglycan biochemistry and tissue regeneration and more than 130 publications. Prof Cool is an Adjunct Professor (Research) in the Department of Orthopaedic Surgery at NUS and is currently Treasurer of TERMIS-AP and Vice-Treasurer of the Singapore Stem Cell Society. He is also Section Editor for the Journal of Molecular Histology and serves on the Editorial Boards of Biomaterials, the Journal of Tissue Engineering and Regenerative Medicine, and Stem Cells and Development. Prof Cool was also co-founder of SMC Biotechnology, an A*STAR spin-off company developing glycosaminoglycan-based medical devices for orthopaedic use.
Zoom
Facebook
Font Resize
A-
A
A+
Print
By
|
The article is contributed/written by
Download the original article
|||
Tags:
; ; ; ; ; ; ; ; ; ; ; ; ;
In The News
View all
Announcements
Sengkang General Hospital Introduces Photon-Counting CT Scanner, Advancing Diagnostic Capabilities for Enhanced Patient Care
23 Apr 2025
Lighternotes
Creating your own AI bots is as easy as ABC (almost)
23 Apr 2025
Research
Genomic analysis provides insight into underpinnings of new treatment combination for deadly, Asian-prevalent lymphoma
16 Apr 2025
Singapore Health
Is 100 the new 50?
16 Apr 2025 | Singapore Health
News Across SingHealth
View all
Announcements
Sengkang General Hospital Introduces Photon-Counting CT Scanner, Advancing Diagnostic Capabilities for Enhanced Patient Care
23 Apr 2025
Lighternotes
Creating your own AI bots is as easy as ABC (almost)
23 Apr 2025
Healthy Living Tips
by
View more
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.
Lung Cancer Prevention and Symptoms
How to Stop Snoring Naturally
Post-Stroke Exercises (Lower Limb Strength Training)
Post-Stroke Exercises (Upper Limb Strength Training)
Related Events
View all
Apr
25
Fri
Healthcare Professionals
NNRIS Bench to Bedside Seminar (Hybrid) - Dr Alfred Sun and Dr Tu Haitao
Zoom
Apr
25
Fri
Healthcare Professionals
Planar Polarity: A Trigger for Neural Development and Cellular Energy Production
NUS
Related Studies
View all
Research News
View all
Research
Genomic analysis provides insight into underpinnings of new treatment combination for deadly, Asian-prevalent lymphoma
16 Apr 2025
Research
Li Ka Shing Foundation and Temasek Trust Jointly Commit S$12 Million to Acquire Systems and Advance Clinical Trial for Innovative Histotripsy Cancer Therapy in Singapore
03 Apr 2025
Last updated on
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Condition & Treatment
Home
Appointment
E-services